@becomingkay2's Victoza weight loss claims, fact-checked
Quick answer
Liraglutide is a GLP-1 receptor agonist that delays gastric emptying and reduces appetite. The SCALE trial showed 8.0% average weight loss at 3.0mg daily (Saxenda dose), while the lower Victoza doses are primarily indicated for diabetes management.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What does this TikTok actually claim?
The video focuses on Victoza (liraglutide) for weight loss, using hashtags that suggest the creator is documenting their injection experience. Without access to the specific claims made in the video content, we can address what viewers typically encounter in Victoza weight loss content.
Most TikTok posts about Victoza discuss injection techniques, side effects, or weight loss results. The hashtags suggest this falls into the personal experience category that's become common on the platform.
What does the science actually say about Victoza?
Victoza contains liraglutide, a GLP-1 receptor agonist originally approved for type 2 diabetes. The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., NEJM, 2015) tested 3.0mg daily liraglutide specifically for weight management.
That study found 8.0% average weight loss at 56 weeks compared to 2.6% with placebo. About 63% of participants lost at least 5% of their body weight. The FDA approved this higher dose as Saxenda, not Victoza, for weight management.
Here's where it gets confusing: Victoza is approved at lower doses (up to 1.8mg daily) for diabetes, not weight loss. Many people use these terms interchangeably, but they're technically different products.
What are people getting wrong about liraglutide?
The biggest misconception is that Victoza and Saxenda are identical. They contain the same drug but at different approved doses for different conditions. Using Victoza off-label for weight loss means you're getting a lower dose than what was studied for obesity.
Many TikTok creators also skip over the significant side effects. In the SCALE trial, 48% of liraglutide users had gastrointestinal side effects versus 28% on placebo. About 9% stopped treatment due to side effects.
The injection technique content can be helpful, but medical supervision matters more than perfect injection form when you're dealing with nausea, vomiting, or other adverse effects.
How does this compare to newer options?
Liraglutide was the first-generation GLP-1 for weight loss, but newer options show better results. The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% weight loss with semaglutide 2.4mg (Wegovy) versus 2.4% with placebo.
Tirzepatide (Zepbound) performed even better in the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022), with 20.9% average weight loss at the highest dose. Both require weekly injections instead of daily like liraglutide.
That doesn't make liraglutide worthless, but it explains why many providers now prescribe the newer agents first. The daily injections alone make liraglutide less convenient.
What should you actually know?
Liraglutide works through legitimate mechanisms: it slows gastric emptying, reduces appetite, and affects brain regions that control food intake. The weight loss is real, just more modest than newer alternatives.
If you're considering any GLP-1 medication, the specific drug matters less than proper medical supervision. These medications can affect blood sugar even in non-diabetics and interact with other conditions.
TikTok experiences can be informative, but they shouldn't replace discussions with healthcare providers who know your medical history. Individual results vary significantly, and what works for one creator might not work for you.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @becomingkay2's Victoza weight loss claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@becomingkay2's Victoza weight loss claims, fact-checked should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
Liraglutide is a GLP-1 receptor agonist that delays gastric emptying and reduces appetite.
FormBlends verdict
Liraglutide is a GLP-1 receptor agonist that delays gastric emptying and reduces appetite. The SCALE trial showed 8.0% average weight loss at 3.0mg daily (Saxenda dose), while the lower Victoza doses are primarily indicated for diabetes management.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Liraglutide is a GLP-1 receptor agonist that delays gastric emptying and reduces appetite. The SCALE trial showed 8.0% average weight loss at 3.0mg daily (Saxenda dose), while the lower Victoza doses are primarily indicated for diabetes management.
- Liraglutide caused 8.0% average weight loss in the SCALE trial at 3.0mg daily (Saxenda dose)
- Victoza contains the same drug but at lower doses approved for diabetes, not weight loss
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Liraglutide caused 8.0% average weight loss in the SCALE trial at 3.0mg daily (Saxenda dose)
- Victoza contains the same drug but at lower doses approved for diabetes, not weight loss
- 48% of participants experienced gastrointestinal side effects in clinical trials
- Newer GLP-1 medications like semaglutide (14.9% weight loss) and tirzepatide (20.9% weight loss) show better results
- Daily liraglutide injections are less convenient than weekly alternatives
- Medical supervision is essential regardless of which GLP-1 medication you choose
- TikTok experiences don't replace proper medical consultation for prescription medications
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
BecomingKay/Comfort Creator⭐️ · TikTok creator
20.2K views on this video
#fyp #victozaweightloss #victozainjection
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by BecomingKay/Comfort Creator⭐️, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.